Furthermore, Food and Drug Administration (FDA) approved the use of bevacizumab in cervical cancer in 2014 [24] suppressing the biological activity of VEGF, which supports our conclusion from the indirect side. This evidence concerns the gene VEGFA and cervical carcinoma.